Evidence grades
Regulatory status
Not FDA-approved for any use; an unapproved research peptide. Not on the FDA's approved 503A compounding bulks list. Sold gray-market as 'research only.' Evidence base is concentrated in a single Russian research program; not independently established in Western peer review.
Summary
Pinealon (also written "EDR," for its amino acids glutamic acid–aspartic acid–arginine) is a synthetic tripeptide — just three amino acids long — developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to a class the group calls "peptide bioregulators," short peptides they propose can enter cells, bind DNA, and tune gene expression in a target tissue (for Pinealon, the brain). It is promoted for sleep, cognition, neuroprotection, and "anti-aging." The honest state of the evidence is that nearly all of it is animal and cell-culture work, much of it from the one originating group, with no independently replicated human trials — and, despite its sleep marketing, no human sleep trial at all.
What people use it for
In biohacker and longevity communities, Pinealon is used (usually by injection, sometimes intranasally or orally) for better sleep, sharper memory and focus, "brain protection," and general anti-aging. The "pineal" in the name leads many to assume a melatonin/circadian connection. The evidence sections test these claims; describing them is not endorsement.
Human evidence
There are no completed, peer-reviewed randomized controlled trials of Pinealon for any indication, and no Phase 1, 2, or 3 trial in the Western indexed literature. The human data that exists comes from the originating Russian program and is small, mostly open-label or observational, and not independently replicated.
The most concrete example reported is an open-label account in which oral Pinealon, added on top of standard therapy in 72 patients with long-term consequences of traumatic brain injury, was associated with improved memory, fewer and less intense headaches, better emotional balance, and fewer errors on a correction test, along with changes in EEG brain-activity measures. Because this was add-on, uncontrolled, single-group work, it cannot separate Pinealon's effect from standard therapy, expectation, or natural recovery — it is a preliminary signal, not proof. Notably, there is no published human trial testing Pinealon for sleep or circadian rhythm, which is one of its most common marketed uses.
Animal / preclinical evidence
This is where essentially all the evidence sits. The most-cited Pinealon-specific primary paper is a 2011 in-vitro study in Rejuvenation Research (Khavinson, Ribakova et al.), which reported that Pinealon dose-dependently limited reactive-oxygen-species buildup and reduced cell death in neurons and other cells under oxidative stress. Rodent work from an affiliated group (Mendzheritsky and colleagues) reported that Pinealon pretreatment altered behavior and apoptosis markers (caspase-3) after induced brain ischemia and hypoxia, and a 2012 rat study (Arutjunyan et al.) reported protection of offspring against prenatal oxidative damage. The most clinically suggestive preclinical work is a 2021 mouse Alzheimer's-model study in Pharmaceuticals reporting that EDR and a related tripeptide preserved dendritic spines and neuroplasticity markers. The proposed mechanism — that the tripeptide enters the cell nucleus and binds specific DNA promoter sequences to modulate transcription — has some independent-methodology support (a 2011 Biochemistry (Moscow) study showed fluorescence-labeled EDR penetrating HeLa-cell nuclei and binding DNA in vitro), but most of the framework comes from the originating group's own computational and biophysical work. The cognition- and mood-related claims trace mechanistically to a 2014 in-vitro finding that short peptides including EDR increased serotonin expression in brain-cortex cells — an interesting cell-culture result, not a demonstrated effect in people.
Two cautions matter here. First, this is preclinical: rodent and in-vitro results do not reliably predict human efficacy or safety, and several of these models use extreme conditions (severe ischemia/hypoxia) far from ordinary human use. Second, the literature is unusually concentrated — the great majority of Pinealon studies, and the DNA-binding mechanism itself, originate from one research lineage and its affiliated labs, with very limited independent replication. That concentration is a reason to treat even consistent-looking animal results as hypothesis-generating rather than settled science.
Anecdotal / community reports
Low-confidence. These are community reports, not evidence. Not medical guidance.
Users commonly report better, deeper sleep and a subjective sense of mental clarity over a cycle of use, often based on a single personal trial rather than any controlled comparison. These reports are the main thing driving Pinealon's sleep reputation, since — as noted above — there is no human sleep trial behind it. They cannot establish efficacy or safety, particularly given that gray-market product quality is unverified.
Doses used in published studies
Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.
Published dosing is not well standardized and comes largely from animal studies and the originating program's protocols rather than from controlled human trials. Because there is no established human trial framework and no approved, quality-controlled product, there is no validated human dose. Community "cycling" protocols circulating online are not derived from published human efficacy trials and are not reproduced here as guidance.
Safety & side effects
The human safety profile is not established, because there are no controlled human trials designed to measure it — no published Phase 1 safety study, and no characterized human pharmacokinetics. The small Russian human reports did not emphasize serious adverse effects, and community reports mention mostly minor, transient issues (e.g., injection-site reactions, brief mild headache) — but absence of reported harm in tiny, uncontrolled studies is not the same as demonstrated safety. The gray-market product-quality risk here is not theoretical: a 2015 analytical study (Vanhee et al., Talanta) by a Belgian official medicines-control laboratory examined illegal and counterfeit injectable peptide preparations seized by authorities and documented identity and purity problems across samples. Because there is no legal, quality-controlled source of Pinealon, a buyer cannot verify a vial's identity, purity, or dose, and long-term effects in humans are simply unknown.
Regulatory / legal status
Pinealon is not FDA-approved for any use and is not a recognized dietary ingredient; it is an unapproved research peptide. It is not on the FDA's approved 503A compounding bulks list, so it cannot be legally compounded as a finished drug, and it is generally sold as a "research only" chemical rather than through any legitimate medical channel. (Some vendor sites assert it can be physician-prescribed and compounded; the more careful reading of the current FDA framework is that no approved compounding pathway exists for it.) Unlike BPC-157 and TB-500, Pinealon is not among the peptides on the FDA's July 2026 advisory-committee agenda. In sport, Pinealon falls under the World Anti-Doping Agency's S0 (non-approved substances) category, making it prohibited for competitive athletes. Status can vary by country and may change; this is not legal advice.
Podcast / media mentions
Pinealon has gained visibility through longevity and peptide-focused podcasts. On the Huberman Lab podcast, it has come up in at least two contexts: a 2026 episode with physician Dr. Abud Bakri (excerpted in the clip "How Pinealon Might Improve Sleep & Cognitive Function"), where it is discussed as potentially increasing REM sleep and improving cognition via effects on gene-expression pathways; and an earlier episode with Dr. Craig Koniver, where Pinealon is discussed for sleep and circadian rhythm (and paired with glycine).
The claim worth scrutinizing is precisely the sleep claim these clips foreground. The discussions present Pinealon's sleep and cognitive effects as promising, and the underlying animal and mechanistic work is real — but it is preclinical and concentrated in one research group, and there is no human sleep trial supporting the REM/sleep claims. So a listener should hear "interesting early-stage hypothesis," not "shown to improve sleep in people." Two specific corrections are worth keeping in mind against common framings: Pinealon is not structurally similar to melatonin (melatonin is not a peptide; the only link is the pineal-gland name), and its sleep reputation rests on animal data plus user reports rather than human trials. The critique here is of the strength claimed for the evidence, not of the people discussing it.
Sources
- Khavinson, Ribakova, Kulebiakin et al. — Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes (Rejuvenation Res. 2011;14(5):535-41) [in-vitro, Pinealon-specific][mechanism]
- Fedoreyeva, Kireev, Khavinson, Vanyushin — Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and specific interaction with DNA (Biochemistry (Moscow). 2011;76(11):1210-9) [DNA-binding mechanism][mechanism]
- Khavinson, Lin'kova, Tarnovskaya et al. — Short peptides stimulate serotonin expression in cells of brain cortex (Bull Exp Biol Med. 2014;157(1):77-80) [in-vitro; basis for cognition/mood claims][mechanism]
- Khavinson, Ilina, Kraskovskaya et al. — Neuroprotective Effects of Tripeptides (EDR/KED) in a Mouse Model of Alzheimer's Disease (Pharmaceuticals. 2021;14(6):515) [animal][animal]
- Arutjunyan, Kozina, Stvolinskiy et al. — Pinealon protects rat offspring from prenatal hyperhomocysteinemia (Int J Clin Exp Med. 2012;5(2):179-185) [animal][animal]
- Anisimov & Khavinson — Peptide bioregulation of aging: results and prospects (Biogerontology. 2010;11(2):139-49) [review summarizing the St. Petersburg program's mostly observational/open-label human claims][observational]
- Umnov, Linkova, Khavinson — Neuroprotective effects of peptide bioregulators in people of various age (Adv Gerontol. 2013) [small open-label human report incl. 72 TBI patients][observational]
- Vanhee, Janvier, Desmedt et al. — Analysis of illegal peptide biopharmaceuticals frequently encountered by controlling agencies (Talanta. 2015;142:1-10) [documents contamination/identity problems in seized peptide products][regulatory]
- Superpower — Pinealon (EDR): A Khavinson-Group Tripeptide in Preclinical Research (physician-reviewed overview; no completed peer-reviewed RCTs; not on FDA compounding list; WADA S0)[media]
- Huberman Lab Clips — 'How Pinealon Might Improve Sleep & Cognitive Function' with Dr. Abud Bakri & Dr. Andrew Huberman (Jun 4, 2026)[media]
- Huberman Lab (Dexa) — 'Pinealon Insights' clip, from the Dr. Craig Koniver episode on peptide & hormone therapies (pinealon + glycine for sleep)[media]